(NASDAQ: TXG) 10x Genomics's forecast annual revenue growth rate of 6.99% is forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 6.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.67%.
10x Genomics's revenue in 2026 is $616,911,000.On average, 17 Wall Street analysts forecast TXG's revenue for 2026 to be $81,568,785,726, with the lowest TXG revenue forecast at $77,888,060,230, and the highest TXG revenue forecast at $85,808,460,333. On average, 17 Wall Street analysts forecast TXG's revenue for 2027 to be $89,622,082,820, with the lowest TXG revenue forecast at $83,224,786,472, and the highest TXG revenue forecast at $96,790,702,884.
In 2028, TXG is forecast to generate $98,599,144,296 in revenue, with the lowest revenue forecast at $87,272,933,061 and the highest revenue forecast at $109,444,581,120.